Despite similar clinical relevance of Gram-positive and Gram-negative infections, immune activation by Grampositive bacteria is by far less well understood than immune activation by Gram-negative bacteria. Our group has made available highly purified lipoteichoic acids (LTA) as a key Gram-positive immunostimulatory component. We have characterized the reasons for lower potency of LT A compared to Gram-negative lipopolysaccharide (LPS), identifying lack of IL-12/IFNy induction as a general characteristic of TLR2 agonists, and need for presentation of L TA on surfaces for enhanced immunostimulatory potency, as major aspects. Aspects of chemokine induction, where L TA is more potent than LPS, have been addressed. Furthermore, novel complement and plant defence activation, as well as CD36 as a new L TA receptor, were identified. The bacterial costimuli and modulators of L TA inducible responses are being investigated: LTA isolated from so far 16 bacterial species, although different in structure, behave remarkably similar while whole live and killed bacteria differ with regard to the pattern of induced responses. The purification and characterization of the respective components of the bacterial cell wall has begun.
Introduction
The clinical symptoms of Gram-positive and Gramnegative sepsis are almost indistinguishable. While immune activation by lipopolysaccharide (LPS, endotoxin), the major constituent of the cell wall of Gramnegative bacteria, has been extensively characterized, the pathogenesis of Gram-positive sepsis has not yet been attributed to a common structural component. The cell
The amphiphilic LT A from most Gram-positive bacterial strains is generally made up of a hydrophilic backbone with repetitive glycerophosphate units and D-alanine or N-acetylglucosamine substituents, and a lipophilic glycolipid anchor. A second type of LT A structure is described for Streptococcus pneumoniae, Streptococcus oraUs and Streptococcus mitis (Abeygunawardana et aI., 1991; Behr et aI., 1992; Fischer, 1997; Hogg et aI., 1997) . The glycerophosphate in the backbone is replaced by a pentamer repeating unit composed of ribitol and a tetrasaccharide. As substituents of the pneumococcal backbone, only phosphory1choline and N-acetyl-D-galactosamine were found. The lipid anchor is usually a dihexosyldiacylglycerol or trihexosyldiacylglycerol, depending on the lipids available in the plasma membrane which differ between species (Fischer, 1988) .
Since the conventional extraction methods resulted in a decomposition of LT A resulting in a decrease in its immunostimulatory potency, we developed a method using butanol/water extraction to isolate highly pure and biologically active L TA from Staphylococcus aureus (Morath et aI., 2001) , the structure of which was elucidated and verified by chemical analysis and synthesis (Stadelmaier et aI., 2003) . Structure-function relationships were investigated by means of different synthetic derivatives by \,IS (Morath et aI., 2002a; Deininger et aI., 2003) and LT A was found to be an agonist of TLR2/6 (Lehner et aI., 2001; Morr et aI., 2002) . A recent publication (Travassos et aI., 2004) , as well as our own findings shows that LT A most likely is a major immunostimulatory principle of PGN, which also possess TLR2 agonistic activity if not sufficiently purified. Furthermore, stimulation with LPS and LT A leads to different cytokine release patterns, which in the case of LT A are .characterized by a strong chemokine induction (von Aulock et aI., 2003) and almost no IL-12 and IFNy induction (Hermann et aI., 2002) , which might be explained by the use of different TLR (Hermann et aI., 2002) . Substitution of IL-12 increases L TA-inducible IFNy release drastically (Hermann et aI., 2002) and LT A has been shown to fail to induce remodelling of the IL-12 promoter (Albrecht et aI., 2004) .
Our further studies focused on the following:
• induction of IL-12 and IFNy by various TLR2 agonists in whole blood; • comparison of IFNy induction of LT A in human and murine cell populations; • synergism between LTA and other Gram-positive products; • identification of IFNy-inducing principle in Grampositive bacteria; • immune stimulatory capacity of LT A bound to surfaces;
• mechanism of enhanced IL-8 release by LT A;
• isolation and characterization of co-stimulatory and modulatory components for LT A action from Grampositive bacteria.
Beside these, collaboration within the DFG high priority program stimulated various collaborative projects, which shall be summarized.
Induction of IL-12 and IFNy by various TLR2 agonists in whole blood
A range of different TLR2 agonists were tested for their ability to induce IFNy in human whole blood (unpublished). These were LTA from S. aureus, Listeria monocytogenes or Lactobacillus plantanum, synthetic Pam3Cys, LPS from B. fragilis and P. gingivalis, PGN from five different species, MALP-2, LT A from Listeria, borrelia lysate, zymosan, pansorbin. Although they all induced TNF release, none of these stimuli were able to induce significant amounts of IFNy. Measurement of IL-12 mRNA induction by the different TLR2 stimuli revealed that the p40 subunit is induced by the TLR2 stimuli, however, at far lower levels than by the same concentration of LPS. Fig. 1 shows representatiVe data for some of the TLR2 agonists employed regarding TNF. The measurements of the ILl2p35 subunit mRNA indicated that this is expressed constitutively and not induced significantly by stimulation with the TLR2 agonists. In conclusion, the poor induction of IL-12 and IFNy appears to be a general characteristic of TLR2 agonists in human whole blood, in line with Human whole blood from four healthy volunteers was incubated in the presence of IOf.lg/ml LTA from S. aureus and L. plantanum, LPS from P. gingivalis and S. abortus equi, B. burgdOljeri N40 lysate and Zymosan from S. cerevisiae for 22 h. TNF release was measured in the cell-free supernatant by ELISA. Data are means±SEM. recent reports on murine macrophages (Hirschfeld et aI., 2001 ).
Comparison of IFNy induction of LT A in human and murine cell populations
To check whether the different TLR2 agonists employed above follow the same cytokine induction pattern in murine as in human cells, they were used to stimulate bone marrow cells of mice. All TLR2 agonists were able to induce the release of the pro-inflammatory monokine IL-6 and were again shown to be dependent on TLR2, however, they differed in their ability to induce IFNy: MALP-2 and PGN from some Grampositive bacterial species induced detectable levels of IFNy in murine bone marrow cells, while Pam3Cys and other PGN, like LTA as shown previously, did not.
To test whether the inability of LT A to stimulate IFNy translates to other immune cell populations, various monocyte and macrophage-containing cell populations were isolated from mice, i.e. bone marrow cells, peritoneal lavage, bronchoalveolar lavage, spleen cells and whole blood. Although LTA induced the release of TNF in all these cell populations, it did not induce IFNy release, except in spleen cells. This observation was followed up by measuring the release of IL-12p40 and IFNy in the same samples. Here, an induction of IL-12p40 above background levels could be observed.
Synergism between LT A and other Gram-positive products Whole blood incubations were performed in which combinations of LT A with Staphylococcal enterotoxin B (SEB), CpG-DNA (synthetic DNA-oligonucleotides) and muropeptides were employed and compared to the inductive capacity of the stimuli by themselves. SEB is a superantigen that induces the release of IFNy by crosslinking MHC II of monocytes and TCR of lymphocytes independent of specifically presented antigens. This induces IFNy release by lymphocytes and TNF release by monocytes. This model was established and characterized in detail by our group (Hermann et aI., 2003) . A matrix of combinations of LT A and SEB concentrations was employed to stimulate whole blood. However, there was no significant increase of the IFNy release by the addition of LT A either after 24 h or after 72 h of incubation (during which time the IFNy level still increases 5-fold).
Neither endotoxin-free muropeptides, e.g. muramyldipeptide (MDP), which are components of the murein sacculus of Gram-positive bacteria, nor CpG-DNA induced significant IFNy release in human whole blood by themselves. MDP is known to synergize with LPS 287 regarding TNF and IFNy induction (Traub et aI. , 2004 (Traub et aI. , , 2006 . However, we found that addition of MDP to LT A was not able to induce IFNy release in human whole bloo,d. In a collaboration using our LT A from S.
aureus and LT A of S. pneumoniae a synergistic effect regarding TNF release was found using PBMC but only in the presence of 2.5% serum (Schroder et aI. , 2003b) .
CpG oligonucleotides have been reported to possess counterinflammatory effects on LPS-induced IFNy release in whole blood (Smith et aI., 2004) , in contrast, they potentiate LPS-induced IFNy by increasing 11;-12 and IL-18 production in rodents (Gould et aI., 2004; Theiner et aI. , 2008) . We could reproduce the finding of Smith et al. in whole blood and found a trend towards increased LTA-induced TNF release and induction of low levels of IFNy by combining L TA and CpG, despite neither component being able to induce IFNy alone. Interestingly, the control oligonucleotides that have a GC sequence instead of CpG had the same effects as the oligonucleotides with the CpG sequence regarding both interaction with LPS and LT A. This implies that these effects are not specific to CpG sequences. The induction of IFNy by the combination of LT A and DNA oligonucleotides could be explained by reports in literature, which describe that the oligonucleotides act via TLR9, i.e. should not interfere with TLR2 mediated LT A signalling, and induce high levels of IL-12 release (Dalpke et aI., 2002) , thereby substituting the missing component necessary to induce IFNy together with the TNF coming from the LTA stimulation. The increase in TNF release can be explained by a positive feedback of IFNy to the monocyte (Hermann et aI., 2003) .
Identification of the IFNy-inducing principle in Gram-positive bacteria
We used differently treated S. aureus to stimulate whole blood. Washed S. aureus were able to induce IFNy release within 24 h of incubation whether they were live, heated to 70 Q C for 30 min, autoclaved, UV-inactivated or sonicated. The higher activity of the live S. aureus compared to the different variations of killed bacteria is probably due to the bacteria still mUltiplying during the incubation time. We also tested whether the bacteria release any stimulatory activity into the medium during culture and found inductive capacity for TNF as well as IFNy release. As we suspected this activity might stem from staphylococcal enterotoxins, the culture supernatant was employed in a 72 h incubation in comparison to SEB, LT A and whole killed S. aureus. After 72 h similar amounts of IFNy had been released by stimulation with 5% of the supernatant as by stimulation with SEB (100 ngj ml). In comparison, even 10 7 killed S. aureus per ml were not able to induce such high levels of IFNy. The release of other lymphokines, i.e. IL-2 and IL-5, was measured in the same samples. Here, neither the S. aureus nor L TA induced IL-2 or IL-5 release; however, the culture supernatant did so, albeit at lower levels than SEB (own unpublished observation). From these results we conclude that the IFNy, IL-2 and IL-5 inducing activity in the culture supernatant was probably an enterotoxin. We further characterized cytokine induction by SEB in isolated cell populations and found that a combination of monocytes and lymphocytes are necessary to induce both IFNy and TNF release (Hermann et aI., 2003) . This implies that the combination of LT A and enterotoxin in Gram-positive infection could complete a cytokine pattern similar to LPS and so result in similar manifestations of disease, despite no synergism of the two components. However, the fact that killed S. aureus induce IFNy implies that also a constitutive IFNy inducing principle exists.
Immune stimulatory capacity of LT A bound to surfaces
Initial observations indicated that overnight binding of LT A to polystyrene surfaces leads to an increased TNF release from whole blood, although the wells were washed twice with saline to remove unbound LT A. To further extend this finding, we incubated L TA and LPS in concentration response curves on a polystyrene plate overnight. The next day the supernatants of all wells were collected and used to stimulate whole blood (Fig. 2,  supernatant) . The wells were washed twice with saline and were incubated with whole blood as well (Fig. 2 , coat) and TNF induction was compared to stimulation with the same concentration of soluble stimulus added together with the blood (Fig. 2, soluble) . We found that as little as 200 ng LT A in the coating solution (coat) per well sufficed to induce TNF release and 20 ng sufficed to induce IL-8 release, while 2).lg of soluble LT A per well was necessary to induce significant cytokine release from whole blood, when given no time for coating. The immunostimulatory potency of the remaining supernatants was comparable to that of freshly added soluble LT A, indicating that only minor quantities of LT A had adhered to the well surface during the overnight incubation. This increased cytokine-inducing activity of coated LTA also translated to IL-lfJ, IL-6 and G-CSF release, while the release of IL-1O was not altered. This was furthermore reflected on the mRNA level. Surprisingly, no such "coat" effect was observed for LPS, as TNF release by the supernatant or by . soluble LPS was greater than that induced by coat LPS at all concentrations (Deininger et aI., in press ).
To determine how much of the LTA had in fact bound to the well surface during the overnight incubation, we developed a protocol to label LTA with rhodamine. The labelling efficiency was 1-2 rhodamine molecules per LT A. The results obtained with the rhodamine-labelled LT A showed that after 24 h of incubation with 2).lg LT A per well, only about 4% of the L TA (i .e. 80 ng) remained bound to the well (Deininger et aI., in press), which is in line with our observation that the supernatant collected from the L TA-coated wells exerted comparable immunostimulatory potency as the same concentration of soluble LTA, and furthermore underlines the enormous increase in potency (about lOOO-fold) in immune activation obtained by surface-presented LT A.
To gain more insight into the type of presentation necessary to increase the stimulatory capacity of LT A, we let LT A interact with different surfaces including polystyrene, polypropylene and glass, which differ in their polarity. We found that although L TA bound to polypropylene in a comparable manner as to polystyrene, only a minor increase in immune stimulation was observed. Furthermore, stimulation of blood with LT A in glass vials induced hardly any cytokine release, independent of whether the L TA was preincubated with the surface or added together with the blood. To rule out possible effects of the silicone-coated glass, we coupled LT A to polymer beads and used these to induce cytokine secretion in the glass vials. These LT A-linked beads, like live and inactivated S. aureus bacteria, were able to stimulate cytokine secretion in silicone borosilicate tubes, showing that the silicone borosilicate surface itself did not interfere with cytokine induction by LT A and this cytokine induction was comparable to that in polypropylene tubes. This indicates that LTA does not adhere to glass and that presentation of LT A is an absolute requirement for immune stimulation by L TA and not only an amplifier of its activity.
The coat effect might be interpreted as the crosslinking of individual LTA molecules. We synthesized, . based on our first synthesis of LT A (Morath et aI., 2002a) , an artificial bisamphiphilic LT A modelling a fixed cross-linkage of two LT A molecules (FigueroaPerez et aI., 2006) . This bisamphiphilic LTA induced higher TNF and IL-8 levels than soluble monoamphiphilic LT A at the same molarity, indicating that the increase in potency of the bound LT A may stem from cross-linkage of receptors. Augmentation of LTA activity by cross-linking has been suggested earlier in experiments with anti-polyglycerophosphate antibodies (Mancuso et aI., 1994) . Together, these results suggest that the increased activity of bound LT A might lie in receptor clustering.
In vivo, the LT A is anchored in the cytoplasmic membrane and projects through the murein sacculus. With regard to induction of immune responses many similarities exist between PGN of Gram-positive bacteria and LT A, like strong induction of IL-8 and dependence on TLR2. Since we showed that PGN from Gram-negative bacteria displays no TLR2-dependent activity, it was tempting to speculate that minor quantities of LT A remaining in PGN preparations might represent a main immune active component. Therefore, we attempted to extract LT A from commercial S. aureus PGN preparation. The elution profile presented both cytokine-inducing activity (TNF and IL-8) and phosphate content (lead activity for LT A) in fractions that typically contain L TA (Fig. 3) Fractions 13-33 contain phosphate, the lead activity for LTA . (Hashimoto et aI., 2007) . Indeed; studies using S. aureus mutants, which lack acylated lipoproteins, show that this S. aureus mutant induces much lower pro-inflammatory cytokine release (Stoll et aI., 2005) compared to the wild-type S. aureus strain, and furthermore leads to lethal disseminated infection in mice by failing to elict adequate immune responses (Bubeck Wardenburg et aI., 2006) . It was further reported that LT A prepared from the S. aureus mutant, lacking acylated lipoproteins, lacks immunobiological activity (Hashimoto et aI., 2006) . The latter publication was rebutted (von Aulock et aI., 2007) by showing that LT A prepared from the same S. aureus mutant possesses cytokine inducing activity comparable to LT A prepared from a wild-type S. aureus strain in human whole blood. Whether this controversy is due to differences in the preparation method or experimental setting remains to be defined. Anyhow, so far, in none of the LTA preparations prepared by our group was lipoprotein contamination detected or isolated. Furthermore, so far no lipoproteins have been extracted from bacteria in high purity or quantity, which could be used to study their immune stimulatory potency.
We investigated the inhibitory properties of polypropylene glycol (PPG), which had previously been attributed with bacteriostatic properties (Chirife et aI., 1983; Whittier et aI., 1992; Ooern and Westerling, 1994; Wasilauskas and Morrell, 1994) , on cytokine induction by Gram-positive immune stimuli. PPG inhibited TNF release in whole blood induced by UV -inactivated S. aureus while cytokine induction by Escherichia coli was only affected at much higher concentrations. Similarly, PPG inhibited cytokine induction by either LTA or PGN from S. aureus, but only interfered partially with LPS-induced cytokine release at lOO-fold higher concentrations (Oraing et aI., in·press), These results further support the hypothesis, that L TA represents the immunostimulatory activity of the PGN of Grampositive bacteria.
Mechanism of enhanced IL-8 release by L TA
We found that LTA from S. aureus in comparison to LPS from Salmonella abortus equi is a more potent inducer of the release of the chemokine IL-8. This was confirmed in 160 healthy individuals of both sexes (Aulock et aI., 2006) and was observed for IL-8 protein as well as for IL-8 mRNA levels. We had already shown in a previous study that the similar strong LTAinducible release of granulocyte colony-stimulating factor (G-CSF) is mediated by cAMP, which binds to a cAMP responsive element (CRE) in the G-CSF promoter (Hareng et aI., 2003) . Since we had also identified a putative CRE in the IL-8 promoter we hypothesized that a strong increase of cAMP by LT A could explain the cytokine profile induced by LT A on a molecular level. Therefore, we inserted the IL-8 promoter region upstream of a luciferase gene and introduced disruptive point mutations into the NFKB and the APl binding as well as in the putative CRE site by sitedirected mutagenesis (Fig. 4A) . While the addition of LPS and LT A resulted in a 3-fold increase of luciferase activity in HL-60 cells transfected with the intact promoter construct (HL-60-WT), the introduction of the construct containing a disrupted NFKB or API binding site led to lO-fold lower basal luciferase levels than HL-60-WT. In contrast, comparable basal and inducible luciferase expression was found in HL-60 cells transfected with the disrupted CRE reporter gene, indicating no functional role of the CRE in mediating IL-8 promoter activity (Fig. 4B, own unpublished  oberservation) . Since LPS is a TLR4 agonist and LT A an agonist of TLR2, it is most likely that differences in signal transduction pathways downstream of the TLRs are responsible for the differences in the cytokine release patterns induced by LPS and LT A. Our recent data show that although activation of the MAP kinases p38 and ERKI/2 is comparable between LPS and LTA, L TA fails to activate Jun kinase (Hermann et aI., 2006) .
In order to identify the blood cell fraction responsible for predominant IL-8 induction by L TA, we isolated PBMC and found that in contrast to whole blood, PBMC stimulation with LPS or LTA resulted in similar IL-8 levels. While the addition of neutrophilic granulocytes had no effect on LPS-or LT A-induced IL-8 levels, the addition of isolated erythrocytes to PBMC resulted in 3-fold higher LT A triggered IL-8 levels compared to LPS. Stimulation with el'ythrocyte fractions alone resulted in no significant IL-8 release. To investigate whether LPS or LT A might be bound by erythrocytes and presented to the immune cells, LT A and LPS were labelled with rhodamine, incubated with erythrocytes and analyzed by FACS. A 3-fold higher rhodamine fluorescence signal was detectable after incubation of labelled LT A compared to LPS, indicating a more pronounced binding of LT A to the erythrocyte in comparison to LPS (own unpublished observation).
Taken together, these findings indicate that possibly by the binding of LT A to erythrocytes, the LT A is presented to the monocytes in a more efficient way, leading to enhanced IL-8 release. This is in line with our general findings that the type of LTA presentation is crucial for its immune stimulating activity, while the potency of LPS is not affected by presentation.
Isolation and characterization of co-stimulatory and modulatory components for LT A action from Grampositive bacteria One of the most prominent differences in the immune activation by LT A versus whole bacteria is the lack of IL-12/IFNy induction. We have shown that bacterial DNA and enterotoxin like SEB might be a synergist complementing LT A in whole bacteria. Since more recently we found that IFNy induction can be obtained also by crude, supernatant-free extracts of bacterial membranes, which are also DNA-free, we speculate that there are also IL-12/IFNy inducing components in the bacterial wall, which were isolated to characterize the S. aureus mediated production of IFNy and to identify the components responsible for the release of this cytokine.
In order to characterize the type of IFNy producing cells, human whole blood was stimulated with S. aureus lysate and IFNy producing cells were analyzed by flow cytometry. Like for LPS, stimulation of whole blood with S. aureus lead to IFNy production by NK-cells and T-cells. Furthermore, the mechanism of IFNy production was found to be completely dependent on IL-12 and TNF release. To identify the IFNy inducing structure of S. aureus the immunostimulatory capacity of different purified bacterial components was investigated in human whole blood. Although on one hand purified S. aureus components like PGN and lipoproteins showed no or low release of IFNy, there is strong evidence for participation of those structures in IFNy induction. For example, the IFNy-inducing capacity of crude extracts was sensitive to both lysozyme and trypsin treatment.
Collaborative further characterization of LT A
In various collaborations, the receptors and binding proteins employed by LT A were characterized, i.e. TLR2 (Lehner et (Triantafilou et aI., 2006) . The following elements of the signal transduction were identified: Bruton's kinase (Liljeroos et aI., 2007) , JNK (Hermann et aI., 2006) , potassium channels (Scheel et aI., 2006) , protein kinase B (Dahle et aI., 2004) , IRAK (Jacinto et aI., 2002; Dahle et aI., 2004) , p38 and ERK (Hermann et aI., 2006 Lotz et aI., 2004 Lotz et aI., , 2006 Hattar et aI., 2006) , cardiac cells (Grandel et aI., 2005) , Kupffer cells (Dahle et aI., 2004) , endothelial cells (Hermann et aI., 2002; Yipp et aI., 2002) and dendritic cells (Michelsen et aI., 2001) . Furthermore, novel mechanisms of complement activation (Lynch et aI., 2004 ) and blood coagulation (Mattsson et aI., 2004) as well as plant immune defence (Zeidler et aI., 2004) were identified. This work currently involving about 80 groups worldwide using highly purified LT A has established this component as an immune-stimulus with biological activities overlapping ·but distinct to LPS. It appears to be a major, though not the only immune-stimulus of Gram-positive bacteria.
Discussion
The dramatic increase in L TA activity due to presentation represents a key finding of this work. This phenomenon explains from our point of view that minor contaminations of PGN by L TA are responsible for the immune stimulatory effects of PGN. Preliminary data indicate that bound LT A still employs CD 14. The role ofTLR2 and the recently identified co-receptor CD36 as well as the LT A binding protein LBP remain to be elucidated. Our data indicate that the effect takes place already on a tr~lllscriptional level. Thus, an augmentation of signal pathways leading to activation of transcription factors is likely. We have been able to show recently that LT A in solution lacks the ability to activate lNK, which might be the underlying reason for lesser potency regarding the induction of pro-inflammatory cytokines. Whether this is changed when LT A is presented on a surface must be explored further.
The enormous potentiation of LT A activity by presentation led to the question of whether LT A monomers in solution can activate monocytes at all. By choosing incubation vials, which do not allow LTA binding, as well as various beads binding LT A, this phenomenon was addressed. In preparation for such studies, a rhodamine-labelled LTA has been produced, which allows tracing and quantification of surface binding. Indeed, when no binding of LT A to surfaces is possible, blood monocytes were not able to react to LT A.
The data presented show that the cytokine pattern induced by LT A is representative for numerous stimuli, which are recognized by TLR2. Induction of IFNy can be realized by co-stimulation of LT A and CpGoligonucleotides, directly with enterotoxin or by presentation of LT A on a surface. A combination of these three factors likely explains why the cytokine spectrum as well as the symptoms of Gram-positive sepsis is so similar to Gram-negative sepsis.
In parallel, numerous collaborations were carried out. While first those endpoints were addressed where LT A fails to match with LPS-inducible cytokine release (IL-12, IFNy), we later addressed those where LTA is often even more potent than LPS, i.e. G-CSF and IL-8 induction. Finally, the identification of synergizing and modifying immune stimuli was initiated.
Altogether, this work has shed light on immune recognition of Gram-positive bacteria. LT A appear to represent a major though not stand-alone immune pattern for recognition of Gram-positive bacteria. Its sensitivity and dependence on surface presentation as well as confusion caused by LPS-contaminated commercial preparations has for a long time prohibited its establishment as the Gram-positive endotoxin.
